Similar articles

• Improving the institutional submission and approval process for clinical research protocols in oncology.

  Camacho LH, Marubio L, Purdom MA, Leonard D, Hong DS, Moulder S, Pilat SR, Kurzrock R. Camacho LH, et al. J Clin Oncol. 2007 Apr 20;25(12):1632-3. doi: 10.1200/JCO.2006.09.5422. J Clin Oncol. 2007. PMID: 17443009 No abstract available.
• Hospice: what to do when anti-cancer therapy is no longer appropriate, effective, or desired.

  Kinzbrunner BM. Kinzbrunner BM. Semin Oncol. 1994 Dec;21(6):792-8. Semin Oncol. 1994. PMID: 7527597 Review. No abstract available.
• Quality of life dimensions that are most important to cancer patients.

  Skeel RT. Skeel RT. Oncology (Williston Park). 1993 Dec;7(12):55-61; discussion 65-6, 69-70. Oncology (Williston Park). 1993. PMID: 7507348 Review.
• Hospice and palliative care: program needs and academic issues.

  von Gunten CF, Neely KJ, Martinez J. von Gunten CF, et al. Oncology (Williston Park). 1996 Jul;10(7):1070-4; discussion 1074, 1079-80. Oncology (Williston Park). 1996. PMID: 8837122
• Must patients with advanced cancer choose between a Phase I trial and hospice?

  Casarett DJ, Karlawish JH, Henry MI, Hirschman KB. Casarett DJ, et al. Cancer. 2002 Oct 1;95(7):1601-4. doi: 10.1002/cncr.10820. Cancer. 2002. PMID: 12237931